Vaccine shows promising results for early-stage breast cancer patients
A new HER2-targeted dendritic cell vaccine has shown promising results in a clinical trial, stimulating an immune response in 80% of patients and inducing regression of early-stage breast tumors. The vaccine was well-tolerated and effective in both invasive and non-invasive disease settings.